Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials
Open Access
- 20 July 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 24 (1), 1-5
- https://doi.org/10.1186/s13054-020-03163-3
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences of the United States of America, 2020
- The proximal origin of SARS-CoV-2Nature Medicine, 2020
- Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus EntryJournal of Virology, 2020
- A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groupsScience Translational Medicine, 2019
- Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trialThe Lancet Respiratory Medicine, 2019
- Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infectionJCI Insight, 2019
- Duration of Antibody Responses after Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2007
- Cumulative Risks of Early Fresh Frozen Plasma, Cryoprecipitate and Platelet Transfusion in EuropeThe Journal of Trauma and Acute Care Surgery, 2006
- Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with PseudotypesEmerging Infectious Diseases, 2005